Seminars in Oncology
Volume 36, Issue 4 , Pages 358-371, August 2009

Other Targetable SarcomasDisclosures

  • Veridiana Pires de Camargo

      Affiliations

    • Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
    • These authors contributed equally to this work.
    • ,
  • Matt van de Rijn

      Affiliations

    • Department of Pathology, Stanford University Medical Center, Stanford, CA
    • These authors contributed equally to this work.
    • ,
  • Enrique de Alava

      Affiliations

    • Molecular Pathology Program, Centro de Investigación del Cáncer–IBMCC, University of Salamanca–CSIC, Salamanca, Spain
    • These authors contributed equally to this work.
    • ,
  • Juan Madoz-Gúrpide

      Affiliations

    • Molecular Pathology Program, Centro de Investigación del Cáncer–IBMCC, University of Salamanca–CSIC, Salamanca, Spain
    • These authors contributed equally to this work.
    • ,
  • Silvana Pilotti

      Affiliations

    • Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
    • ,
  • Margaret von Mehren

      Affiliations

    • Sarcoma Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • These authors contributed equally to this work.
    • ,
  • Florence Pedeutour

      Affiliations

    • Laboratoire de Génétique des Tumeurs Solides, Faculté de Médecine, Centre Hospitalier Universitaire de Nice et CNRS UMRS 6543, Nice, France
    • These authors contributed equally to this work.
    • ,
  • Robert G. Maki

      Affiliations

    • Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
    • These authors contributed equally to this work.
    • ,
  • Piotr Rutkowski

      Affiliations

    • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland
    • These authors contributed equally to this work.
    • ,
  • David M. Thomas

      Affiliations

    • Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to David M. Thomas, FRACP, PhD, Research Division, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria 3002, Australia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Enrique de Alava is supported by the European Commission (NoE EuroBoNet), Ministry of Science and Innovation of Spain-FEDER (PI052524, RD06/0020/0059). Silvana Pilotti is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC). Robert G. Maki is supported by Program Project Grant No. P01-CA47179; Cycle for Survival. David M. Thomas is supported by the Victorian Cancer Agency Clinician Researcher fellowship, and Cancer Australia.

Disclosures Robert G. Maki: Research support (Pfizer); honoraria (Ziopharm); testimony (Roche)Margaret von Mehren: Research support (Novartis, Pfizer, Johnson & Johnson); consultation fees (Novartis, Pfizer, Medimmune)David Thomas: Research support (Novartis, Amgen, Pfizer)

PII: S0093-7754(09)00108-0

doi:10.1053/j.seminoncol.2009.06.008

Refers to erratum:

Seminars in Oncology
Volume 36, Issue 4 , Pages 358-371, August 2009

Article Tools

* Image Usage & Resolution